These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29410031)

  • 21. Risk factors for granulomas in children following immunization with aluminium-adsorbed vaccines: A Danish population-based cohort study.
    Hoffmann SS; Thiesson EM; Johansen JD; Hviid A
    Contact Dermatitis; 2022 Nov; 87(5):430-438. PubMed ID: 35778959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aluminium adjuvants in vaccines - A way to modulate the immune response.
    Danielsson R; Eriksson H
    Semin Cell Dev Biol; 2021 Jul; 115():3-9. PubMed ID: 33423930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aluminum vaccine adjuvants: are they safe?
    Tomljenovic L; Shaw CA
    Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.
    Wilson NS; Duewell P; Yang B; Li Y; Marsters S; Koernig S; Latz E; Maraskovsky E; Morelli AB; Schnurr M; Ashkenazi A
    J Immunol; 2014 Apr; 192(7):3259-68. PubMed ID: 24610009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease.
    Gherardi RK; Aouizerate J; Cadusseau J; Yara S; Authier FJ
    Morphologie; 2016 Jun; 100(329):85-94. PubMed ID: 26948677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunisation with aluminium-containing vaccine of a child with itching nodule following previous vaccination.
    Frederiksen MS; Tofte H
    Vaccine; 2004 Nov; 23(1):1-2. PubMed ID: 15519700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines.
    Bergfors E; Björkelund C; Trollfors B
    Eur J Pediatr; 2005 Nov; 164(11):691-7. PubMed ID: 16044278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Itching nodules and hypersensitivity to aluminium after the use of adsorbed vaccines from SSI.
    Thierry-Carstensen B; Stellfeld M
    Vaccine; 2004 May; 22(15-16):1845. PubMed ID: 15121293
    [No Abstract]   [Full Text] [Related]  

  • 30. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations.
    Mold M; Shardlow E; Exley C
    Sci Rep; 2016 Aug; 6():31578. PubMed ID: 27515230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.
    Petrovsky N
    Drug Saf; 2015 Nov; 38(11):1059-74. PubMed ID: 26446142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term regulation of local cytokine production following immunization in mice.
    Nakayama T; Kashiwagi Y; Kawashima H
    Microbiol Immunol; 2018 Feb; 62(2):124-131. PubMed ID: 29266448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. About the alleged toxicity of aluminium-based adjuvants in vaccines: All published studies should be taken into account.
    Goullé JP; Couvreur P; Grangeot-Keros L
    Int J Pharm; 2021 Jun; 602():120656. PubMed ID: 33932540
    [No Abstract]   [Full Text] [Related]  

  • 34. [Vaccines: intradermal, poliomyelitis, aluminum].
    Nau JY
    Rev Med Suisse; 2012 Nov; 8(364):2308-9. PubMed ID: 23240250
    [No Abstract]   [Full Text] [Related]  

  • 35. [Influence of aluminum adjuvant to experimental rabies vaccine].
    Lin H; Perrin P
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):133-5. PubMed ID: 12569779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is exposure to aluminium adjuvants associated with social impairments in mice? A pilot study.
    Sheth SKS; Li Y; Shaw CA
    J Inorg Biochem; 2018 Apr; 181():96-103. PubMed ID: 29221615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.
    Destexhe E; Prinsen MK; van Schöll I; Kuper CF; Garçon N; Veenstra S; Segal L
    J Pharmacol Toxicol Methods; 2013; 68(3):367-73. PubMed ID: 23624216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent itching nodules after the fourth dose of diphtheria-tetanus toxoid vaccines without evidence of delayed hypersensitivity to aluminium.
    Netterlid E; Bruze M; Hindsén M; Isaksson M; Olin P
    Vaccine; 2004 Sep; 22(27-28):3698-706. PubMed ID: 15315849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on adjuvants for human prophylactics. II. Influence of the route of injection on the activity of adjuvants to tetanus toxoid in guinea pigs.
    Yamamoto A; Murata R
    Jpn J Med Sci Biol; 1978; 31(5-6):393-406. PubMed ID: 156804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aluminum adjuvant potentiates gilthead seabream immune responses but induces toxicity in splenic melanomacrophage centers.
    Galindo-Villegas J; García-Alcazar A; Meseguer J; Mulero V
    Fish Shellfish Immunol; 2019 Feb; 85():31-43. PubMed ID: 29510253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.